Skip to main content

HEALTH

  • Turning to OTCs as first line of therapy only makes cents

    Just about every healthcare practitioner recommends over-the-counter medicines to their patients. And nearly 3-out-of-4 make that OTC recommendation as the first therapy option, according to a recent survey released by the Consumer Healthcare Products Association. 

    This is another proof point that OTC medicines play an important role in holding down cost. 

  • Benzocaine warning helps Hyland's sales

    SILVER SPRING, Md. — Last year the Food and Drug Administration warned parents against using the ingredient benzocaine in children to relieve oral pain. Children under the age of 2 years who are teething and given benzocaine should be under the supervision of a doctor, the agency warned.

  • Switching off the pain

    LAKE FOREST, Ill. — Omron recently charged analgesic aisles with a new pain relief option. Omron's Electro-Therapy Pain Relief unit is the only approved transcutaneous electrical nerve stimulation unit on the market and should be an adjunctive sale for chronic pain sufferers. The product could add a spark to nonmedicinal, external pain relief. Sales of heat and ice packs were relatively flat in 2012, with sales approaching $235 million.

  • Study: Colder days may contribute to more virulent flu season

    BETHESDA, Md. — Global warming could spell the end of flu seasons, research released Friday by the National Institution of Health suggests, because the influenza virus better propagates and is more sustainable in colder climates. 

  • Oceans Omega introduces omega-infused water

    PARAMUS, N.J. — Oceans Omega launched its omega-3 EPA/DHA enhanced water product, branded Omega Infusion, into 100 H-E-B stores with Healthy Living Departments, the company announced.

  • Branded pain relief tablets battle for sales

    With private label across analgesics up an estimated 11.3% to $1.7 billion, retailers are going to need to make some tough decisions as two internal analgesic powerhouses — McNeil's Tylenol and Novartis' Excedrin — make their way back onto market after respective recalls. Within internal analgesic tablets, sales of store brand equivalents were up 15% off of a 2011 base of around $1.2 billion. The branded competition also were benefactors — both Pfizer's Advil and Bayer's Aleve generated more than $50 million in incremental sales on top of 2011 sales.

  • At-home tests grow in popularity

    BETHLEHEM, Pa. — The landmark launch of Orasure Technologies' OraQuick In-Home HIV test last year was a key driver behind the 5.4% growth in the home-test kit category for the 12 weeks ended Dec. 30 across U.S. multi-outlets, according to SymphonyIRI Group data. The HIV test contributed $1 million in purely incremental sales to the total $15.5 million in category sales.

  • Arco Health introduces weight-loss gum

    BELLEFONTAINE, Ohio — Arco Health Inc. announced this week the release of a new chewing gum designed to aid users in losing weight and to keep their appetites in check. New Diet-Burst Gum is formulated to make a person feel fuller and quell cravings between meals.

X
This ad will auto-close in 10 seconds